Prospective analysis of the impact of adjuvant treatment with external beam radiation therapy and vaginal brachytherapy on health-related quality of life in patients with early-stage endometrioid endometrial carcinoma
Ginekologia Polska · 2023
DOI: 10.5603/gp.a2023.0007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ginekologia Polska, 2023. Verfasst von Adam Kluska und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Brachytherapy, Greater Poland Cancer Centre, Poznan, Poland. adamkluska88@gmail.com. Hauptthemen laut MEDLINE: Quality of Life, Endometrial Neoplasms, Brachytherapy, Carcinoma, Endometrioid.
Abstract (Originalsprache)
OBJECTIVES: Our study evaluates the impact of adjuvant treatment with external beam radiotherapy (EBRT) combined with vaginal high dose rate brachytherapy (HDR BT) on health related quality of life (HRQL) in patients with early stage endometrioid endometrial carcinoma. MATERIAL AND METHODS: From March 2019 to February 2021, 60 patients were enrolled with early stage endometrioid endometrial carcinoma, and qualified to adjuvant treatment after hysterectomy. HRQL was assessed using the EORTC QLQ-C30 questionnaire, with the endometrial cancer-specific HRQL module EORTC QLQ-EN24. Questionnaires were completed in four timepoints during adjuvant radiotherapy. RESULTS: A significant decrease in mean global health status / quality of life (p < 0.001) and role functioning (p = 0.028) was noted, as assessed in EORTC QLQ-C30 scale. Among the EORTC QLQ-C30 symptoms scales, significant differences were noted in the fatigue scale (p = 0.003), pain scale (p = 0.001), constipation scale (p < 0.001) and diarrhea scale (p < 0.001) over time. The EORTC QRQ-EN24 analysis showed significant deterioration in the urological symptoms scale (p < 0.001), gastrointestinal symptoms scale (p < 0.001) and in the mean pain in back and pelvis scale (p = 0.003). CONCLUSIONS: Adjuvant radiotherapy in patients with early-stage endometrioid endometrial cancer after hysterectomy is associated with worse quality of life, especially due to the toxicity of the treatment in relation to the gastrointestinal tract and urinary system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Brachytherapy, Greater Poland Cancer Centre, Poznan, Poland. adamkluska88@gmail.com.
- Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland.
- Department of Teleradiotherapy, Regional Cancer Centre, Copernicus Memorial Hospital of Lodz, Poland.
- Department of Radiotherapy and Oncological Gynecology, Greater Poland Cancer Center, Poznan, Poland.
- Department of Radiotherapy, Chair of Oncology, Medical University of Lodz, Poland.
ORCID-Profile: Adam Kluska, Bartlomiej Tomasik, Jacek Fijuth, Leszek Gottwald
Zitieren
APA
Kluska, A., Tomasik, B., Moszynska-Zielinska, M., Zytko, L., Tracz, N., Spych, M., Fijuth, J., & Gottwald, L. (2023). Prospective analysis of the impact of adjuvant treatment with external beam radiation therapy and vaginal brachytherapy on health-related quality of life in patients with early-stage endometrioid endometrial carcinoma. Ginekologia Polska. https://doi.org/10.5603/gp.a2023.0007
Vancouver
Kluska A, Tomasik B, Moszynska-Zielinska M, Zytko L, Tracz N, Spych M, et al. Prospective analysis of the impact of adjuvant treatment with external beam radiation therapy and vaginal brachytherapy on health-related quality of life in patients with early-stage endometrioid endometrial carcinoma. Ginekologia Polska. 2023. doi:10.5603/gp.a2023.0007
BibTeX
@article{Kluska2023,
author = {Kluska, Adam and Tomasik, Bartlomiej and Moszynska-Zielinska, Malgorzata and Zytko, Leszek and Tracz, Natalia and Spych, Michal and Fijuth, Jacek and Gottwald, Leszek},
title = {Prospective analysis of the impact of adjuvant treatment with external beam radiation therapy and vaginal brachytherapy on health-related quality of life in patients with early-stage endometrioid endometrial carcinoma},
journal = {Ginekologia Polska},
year = {2023},
doi = {10.5603/gp.a2023.0007}
}
EUVIMED